Fortis Life Sciences acquires Abcore

By The Science Advisory Board staff writers

March 4, 2022 -- Fortis Life Sciences has acquired Abcore, extending Fortis’ capabilities into the antibody discovery market serving biopharma customers developing antibody and nanobody-based therapeutics.

Abcore provides antibody and nanobody products and services. Abcore has built an entire platform for nanobody and single domain (VHH) antibody discovery, based on proprietary phage display libraries.

Fortis Life Sciences is a strategic platform company providing capital, expertise, and operational resources to enable the growth and success of founder-led life sciences tools companies.

Financial details of the acquisition were not disclosed.

CellCarta acquires Biogazelle
CellCarta announced the acquisition of Biogazelle to strengthen its genomic capabilities and expand into digital polymerase chain reaction services.
Thermo Fisher announces new spectrometers, facility, more
Thermo Fisher Scientific announced that it is building a manufacturing facility in Tennessee. In addition, it has released a line of spectrometers and...
Abcore develops antibodies against COVID-19
Antibody research and development firm Abcore said that it's discovered and tested a panel of functional therapeutic candidates for the treatment of COVID-19.

Copyright © 2022

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter